Biocon gets a shot in the arm with FDA approval for insulin glargine

The drug will be major contributor in the firm's bid to reach $1 billion revenue target by FY22, says biologics CEO Hamacher

A top executive of biopharmaceutical major Biocon, which has received the US Food and Drug Administration (FDA) approval for the biosimilar insulin glargine, says the drug will be a major contributor to the company’s revenue target of $1 billion through its biologics division by FY22. The drug was co-developed with Mylan. 

“The US market represents a great opportunity given that there is only one biosimilar glargine currently available. Glargine is a $2.2 billion market and we believe this product will be an important contributor to our growth in fiscal year FY21 and beyond,” said Christiane Hamacher, CEO & Managing Director,